Legend Strategy International Holdings Group Announces Supplemental Details on Discloseable Acquisition of Auro Hong Kong Limited Shares
Hong Kong, 3 March 2026 – Legend Strategy International Holdings Group Company Limited (“the Company”; Stock Code: 1355) has issued a supplemental announcement regarding its previously disclosed acquisition of shares in Auro Hong Kong Limited, an event constituting a discloseable transaction. This update provides investors and shareholders with critical new details on the business, financials, and future prospects of Beisheng Biotechnology Group, the underlying asset acquired, as well as the management and funding of the transaction.
Key Points of the Announcement
- Acquisition Structure & Funding: The Company is acquiring shares in Auro Hong Kong Limited, with the initial payment of HK\$15 million funded via interest-free borrowings from Osibao Cosmetics International Limited (the Company’s largest shareholder, holding 28.99%). The remaining HK\$7 million will also be funded interest-free by Osibao. There are currently no further funding obligations for the Group in relation to the acquisition.
- Business Model of Beisheng Biotechnology: Beisheng operates as an integrated platform providing cost-effective DNA/strain manufacturing and related data production services, leveraging:
- Sales and subscription of proprietary design software (Tosycon®)
- Manufacturing and sales of vectors, target organisms, reagents, and laboratory materials
- Consultation and solutions based on its self-developed bio-manufacturing standard (ArchiCel®)
- Competitive Advantages: Beisheng’s platform is designed to reduce supply costs, streamline design-to-manufacturing processes, and lower the skills barrier for senior R&D staff, thereby delivering greater efficiency to clients.
- Financial Performance:
- 2023 Revenue: RMB 1.81 million (beer sales, software/services, vectors/organisms)
- 2024 Revenue: RMB 3.95 million (significant growth in software/services and vectors/organisms)
- First 11 months of 2025: RMB 487,000 (notably reduced, reflecting a strategic shift towards full-scale product launch in 2026)
- Client Base: Beisheng’s customers include both local Chinese and multinational enterprises across agriculture, biotechnology, alcoholic beverage, biomedical, and laboratory services sectors.
- Strategic Focus in 2025: Beisheng reduced pre-commercial sales to focus on refining its bioinformatics software (Tosycon®) and proprietary vector/strain architecture (ArchiCel®), preparing for a full commercial launch in 2026.
- Investment in Fermentation: Beisheng holds a 20% equity interest in Yanwu Tongzao (Zhongshan) Technology Co., Ltd. (“Yanwu”), which utilizes Beisheng’s fermentation technology to produce and sell alcoholic beverages, soft drinks, and food products.
- Management & Oversight: The Group’s management team includes more than 10 experienced staff and consultants with expertise in R&D, marketing, production, and quality control. Upon completion, the Group can appoint up to two directors on Beisheng’s five-member board, ensuring direct oversight of daily operations and performance reporting.
Shareholder Impact & Price Sensitive Information
- Potential Share Price Impact: The acquisition represents a strategic expansion into biotechnology and synthetic biology, leveraging Beisheng’s innovative platform and technology. This could materially impact future revenue streams if the full-scale commercial launch in 2026 is successful.
- Funding by Major Shareholder: The transaction is being financed interest-free by the Company’s major shareholder, Osibao Cosmetics International Limited. This supports the Group’s liquidity but also highlights close related-party involvement.
- Conditional Completion: Shareholders should note that the acquisition is subject to fulfillment of conditions precedent in the Sale and Purchase Agreement and may or may not proceed. Caution is advised in trading the Company’s shares until completion is confirmed.
Management Strength and Integration Plans
The Group’s management team is highly experienced, with the head of R&D having over a decade of industry experience and success in medical device and biomedical product development. The production head is a licensed pharmacist with over 20 years in healthcare and beauty production management. This expertise will be leveraged to supervise and collaborate with Beisheng Biotechnology post-acquisition, ensuring alignment and integration.
Conclusion
This supplemental announcement provides significant transparency regarding the strategic rationale, operational integration, and financial implications of the Company’s investment in Auro Hong Kong Limited and Beisheng Biotechnology. The shift in Beisheng’s business model towards a full-scale launch in 2026, coupled with the Company’s direct management oversight and robust funding support, positions the Group for potential value creation in the high-growth biotech sector. However, as the acquisition is not yet completed and future performance will depend on successful commercialization, investors are urged to remain vigilant.
Disclaimer: The above is a summary of a supplemental announcement by Legend Strategy International Holdings Group Company Limited and does not constitute investment advice. Completion of the acquisition is subject to contractual conditions and may not proceed. Investors should exercise caution and consult professional advisers before making any investment decisions based on this announcement.
